Article
Vebreltinib for Previously Treated Astrocytoma, IDH-Mutant, Grade 4, and Glioblastoma, IDH Wild-Type with PTPRZ1-MET Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial.
Cancer communications (London, England) - 1 Jan 2026
Bao Zhaoshi, Xue Yake, Liu Yanhui, Li Shouwei, Wang Liang, Qu Yan, Mou Yonggao, Yu Rutong, Wu Jinsong, Yao Yu, Shu Kai, Hu Guangyuan, Cai Linbo, Li Wenbin, Qiu Xiaoguang, Li Yunqian, Zhang Lei, Qi Songtao, Ji Ying, Ma Chunxiao, Ma Wenbin, Li Gang, Tao Rongjie, Sun Chongran, Chen Ligang, Lv Sheng-Qing, Liang Peng, Pan Hao, Peter Woo Yat Ming, Danny Chan Tat Ming, Mao Qing, Wei Xinting, Jiang Tao
Abstract excerpt
Background: High-grade gliomas, including isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH wild-type glioblastoma, have a poor prognosis and limited treatment options. The PTPRZ1-MET (ZM) fusion gene is a potential therapeutic target. This study evaluated vebreltinib, a highly selective, adenosine-triphosphate-competitive inhibitor of the mesenchymal-epithelial transition factor (MET), in patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.